Evidence Hub

Open-label, Double-arm, Controlled, Randomized, Multicentre Clinical Trial to Evaluate the Impact of Pharmacogenetic-guided Treatment in Patients With Insufficiently Controlled Type 2 Diabetes

ClinicalTrials.gov · COMPLETED, 2026

92 participants

Abstract

The goal of this clinical trial is to assess the efficacy of a pharmacogenetics-guided treatment, compared to standard optimized treatment, in patients with inadequately controlled type 2 diabetes. The main questions it aims to answer are:

* Is the disease better controlled when the treatment prescribed is based on the participant's pharmacogenetic profile?

* What medical problems do participants experience while taking the treatment?

Participants will:

* Take the treatment described according to the Summary of Product Characteristics (SmPC).

* Visit the clinic once every 12 weeks for checkups and tests.

* Keep a diary of their symptoms to inform the Investigator.

Conditions: Diabetes Mellitus Type 2.

Primary outcome: Comparison of HbA1c ≤7% goal at Week 24 between Pharmacogenetic-Guided and Standard Treatment in Type 2 Diabetes.

Enrollment: 92 participants.

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 92 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free